MyLungCancerTeam

Entrectinib (Rozlytrek) is a treatment for non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene. Here are some key points about Entrectinib:

- Mechanism: It targets ROS1 fusion proteins inside cancer cells, blocking signals that help the cancer grow
- Show Full Answer

Entrectinib (Rozlytrek) is a treatment for non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene. Here are some key points about Entrectinib:

- Mechanism: It targets ROS1 fusion proteins inside cancer cells, blocking signals that help the cancer grow.
- Administration: Taken orally once per day, as prescribed by a physician.
- Common Side Effects: Tiredness, constipation, change in taste, swelling.

For clinical trials, it's important to discuss with your healthcare provider. They can help you find trials specific to ROS1 gene mutations and your stage of NSCLC.

Regarding supplements, always consult your doctor before starting any new supplements, as they can interact with your treatment.

For more detailed information, you can visit the following resources:
- [Treatments for Lung Cancer](https://www.mylungcancerteam.com/resources/trea...)
- [Rozlytrek (Entrectinib) for Lung Cancer](https://www.mylungcancerteam.com/treatments/roz...)
- [Clinical Trials for NSCLC](https://www.mylungcancerteam.com/resources/clin...)

Stay strong and best of luck with your treatment!

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Clinical Trials for NSCLC: What To Ask Your Doctor | MyLungCancerTeam

Rozlytrek (Entrectinib) for Lung Cancer | MyLungCancerTeam